Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome

Kaiser, T.; Langhorst, J.; Wittkowski, H.; Becker, K.; Friedrich, A. W.; Rueffer, A.; Dobos, G. J.; Roth, J.; Foell, D.
December 2007
Gut;Dec2007, Vol. 56 Issue 12, p1706
Academic Journal
Objective: S100A12 is a pro-inflammatory protein that is secreted by granulocytes. S100A12 serum levels increase during inflammatory bowel disease (IBD). We performed the first study analysing faecal S100A12 in adults with signs of intestinal inflammation. Methods: Faecal S100A12 was determined by ELISA in faecal specimens of 171 consecutive patients and 24 healthy controls. Patients either suffered from infectious gastroenteritis confirmed by stool analysis (65 bacterial, 23 viral) or underwent endoscopic and histological investigation (32 with Crohn's disease, 27 with ulcerative colitis, and 24 with irritable bowel syndrome; IBS). Intestinal S100A12 expression was analysed in biopsies obtained from all patients. Faecal calprotectin was used as an additional non-invasive surrogate marker. Results: Faecal S100A12 was significantly higher in patients with active IBD (2.45 ± 1.15 mg/kg) compared with healthy controls (0.006 ± 0.03 mg/kg; p<0.001) or patients with lBS (0.05 ± 0.11 mg/kg; p<0.001). Faecal S100A12 distinguished active IBD from healthy controls with a sensitivity of 86% and a specificity of 100%. We also found excellent sensitivity of 86% and specificity of 96% for distinguishing IBD from lBS. Faecal S100A12 was also elevated in bacterial enteritis but not in viral gastroenteritis. Faecal S100A12 correlated better with intestinal inflammation than faecal calprotectin or other biomarkers. Conclusions: Faecal S100A12 is a novel non-invasive marker distinguishing IBD from lBS or healthy individuals with a high sensitivity and specificity. Furthermore, S100A12 reflects inflammatory activity of chronic IBD. As a marker for neutrophil activation, faecal S100A12 may significantly improve our arsenal of non-invasive biomarkers of intestinal inflammation.


Related Articles

  • Role of alkaline phosphatase in colitis in man and rats. A Tuin // Gut;Mar2009, Vol. 58 Issue 3, p379 

    BACKGROUND AND AIMS: Crohn’s disease (CD) and ulcerative colitis (UC) are chronic multifactorial inflammatory bowel diseases (IBDs) with unknown aetiology, but a deregulated mucosal immune response to gut-derived bacterial antigens is thought to be involved. Toll-like receptor ligands,...

  • Molecular prediction of disease risk and severity in a large Dutch Crohn’s disease cohort. R K Weersma // Gut;Mar2009, Vol. 58 Issue 3, p388 

    BACKGROUND: Crohn’s disease and ulcerative colitis have a complex genetic background. We assessed the risk for both the development and severity of the disease by combining information from genetic variants associated with inflammatory bowel disease (IBD). METHODS: We studied 2804...

  • Inflammatory Bowel Disease.  // Current Medical Literature: Gastroenterology;2007, Vol. 26 Issue 3, p82 

    The article presents studies related to inflammatory bowel disease. These include "Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease," by J. W. Winter et al,...

  • Infections and Inflammatory Bowel Disease.  // Current Medical Literature: Gastroenterology;2008, Vol. 27 Issue 3, p91 

    The article highlights studies related to infections and inflammatory bowel disease (IBD). In "Excess hospitalisation Burden Associated with Clostridium Difficile in Patients with Inflammatory Bowel Disease," the authors examined the outcomes of patients with C difficile infection and...

  • Inflammatory Bowel Disorders.  // Current Medical Literature: Gastroenterology;2011, Vol. 30 Issue 1, p21 

    The article discusses various research that explored the different aspects of inflammatory bowel disorders. One of the studies dealt with the changes in surgical resection rates and medical treatments for Crohn's disease. Another research focused on the association of pre-operative management...

  • Frequency of Bone Marrow Toxicity by Using Pattern of Azathioprine in Inflammatory Bowel Disease Patients. Kyung Hee Hyun; Suck-Ho Lee; Jae Min Shin; Dong Il Park; Chang Kyun Lee; Jeong Eun Shin; Chang Soo Eun; Kyu Chan Huh; Young Hwangbo // Intestinal Research;2012, Vol. 10 Issue 3, p244 

    Background/Aims: The most important adverse effect of azathioprine (AZA) is bone marrow toxicity (BMT). Many physicians have preferred a gradual dose increment (GDI) policy for the prevention of BMT. The aim of this study was to evaluate the efficacy of GDI for the prevention of AZA-induced BMT...

  • New therapeutic approach in inflammatory bowel disease. PAPA, A.; MOCCI, G.; SCALDAFERRI, F.; BONIZZI, M.; FELICE, C.; ANDRISANI, G.; GASBARRINI, A. // European Review for Medical & Pharmacological Sciences;Jan2009 Supplement, Vol. 13 Issue S-1, p33 

    In the last decade, biologic agents, in particular infliximab and adalimumab, have deeply changed the therapeutic armamentarium of inflammatory bowel disease (IBD). However, these drugs have a number of contraindications and side-effects that physicians should know so to avoid and eventually...

  • Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Bernstein, Charles N.; Shanahan, Fergus // Gut;Sep2008, Vol. 57 Issue 9, p1185 

    The article offers a perspective on some of the more consistent epidemiological observations in inflammatory bowel diseases (IBD). It attempts to reconcile them with current concepts of disease mechanisms. The article discusses the environmental or lifestyle risk factors associated with IBD. It...

  • "It doesn't do any harm, but patients feel better": a qualitative exploratory study on gastroenterologists' perspectives on the role of antidepressants in inflammatory bowel disease. Mikocka-Walus, Antonina A; Turnbull, Deborah A; Moulding, Nicole T; Wilson, Ian G; Andrews, Jane M; Holtmann, Gerald J // BMC Gastroenterology;2007, Vol. 7, p38 

    Background: Interest in psychological factors in patients with inflammatory bowel disease (IBD) has increased in recent years. It has even been proposed that treating psychological co-morbidities with antidepressants may control disease activity and improve quality of life. Despite this, there...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics